IP Library Granted Patent US 9,630,986
Granted Patent B2
US 9,630,986 · App. 14/132,386 · Granted Apr 25, 2017

Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same

Inventors: Douglas Covey (St. Louis, MO); Albert Jean Robichaud (Ringoes, NJ)
Assignees: Washington University; Sage Therapeutics, Inc.
C07J1/0029C07J1/0011C07J1/0018C07J5/0015C07J7/002C07J21/00C07J41/0005C07J41/0094C07J21/006C07J21/008C07J41/0016C07J51/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,630,986
App. No.
14/132,386
Granted
Apr 25, 2017
Kind
B2
Abstract

The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

Claims (40)

1. A compound of Formula (I-g):

or a pharmaceutically acceptable salt thereof;

wherein:

R 1 is selected from (C 1 -C 4 alkyl)-O, spirooxirane, cyano, ═O, nitro, (C 1 -C 4 alkyl)C(O), and HO(C 1 -C 4 alkyl)C(O);

R 2 is ═O, H, or OR a , where R a is selected from H, optionally substituted C 1 -C 4 alkyl, or optionally substituted aryl, with the proviso that when R 2 is ═O, R 8 is not present;

R 3 is H, optionally substituted C 1 -C 4 alkyl, optionally substituted C 2 -C 4 alkenyl, optionally substituted C 2 -C 4 alkynyl, or optionally substituted aryl;

R b is methyl;

R 8 , when present, is H or optionally substituted C 1 -C 4 alkyl;

- - - denotes an optional, additional C—C bond, resulting in a C═C bond between C 16 -C 17 , with the proviso that when present, the R 1 is not ═O or spirooxirane.

2. The compound of claim 1 , wherein the R 3 group is selected from the group consisting of H, methyl, and trifluoromethyl.

3. The compound of claim 1 , wherein R 2 is ═O, methoxy or H.

4. The compound of claim 1 , wherein R 1 is beta-cyano.

5. The compound of claim 1 selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

6. The compound of claim 1 , wherein

R 1 is selected from (C 1 -C 4 alkyl)-O, spirooxirane, cyano, ═O, (C 1 -C 4 alkyl)C(O), and HO(C 1 -C 4 alkyl)C(O).

7. A compound of the formula:

or a pharmaceutically acceptable salt thereof.

8. A compound of the formula:

or a pharmaceutically acceptable salt thereof.

9. A compound of the formula:

or a pharmaceutically acceptable salt thereof.

10. A compound of the formula:

or a pharmaceutically acceptable salt thereof.

11. A compound of the formula:

or a pharmaceutically acceptable salt thereof.

12. A compound of the formula:

or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a compound of formula:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

14. A pharmaceutical composition comprising a compound of formula:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

15. A pharmaceutical composition comprising a compound of formula:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

16. A pharmaceutical composition comprising a compound of formula:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

17. A pharmaceutical composition comprising a compound of formula:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

18. A pharmaceutical composition comprising a compound of formula:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

Assignments (3)
CONFIRMATORY LICENSE Recorded Apr 3, 2017
From: WASHINGTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042134/0522 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2016
From: COVEY, DOUGLAS
To: WASHINGTON UNIVERSITY
Reel/Frame 039368/0084 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2016
From: ROBICHAUD, ALBERT JEAN
To: SAGE THERAPEUTICS, INC.
Reel/Frame 039368/0409 →
Continuity (2)
Provisional Application 61738822 · Dec 18, 2012
Related Publication 20140235600A1 · Aug 21, 2014